Atherosclerosis
Volume 205, Issue 1 , Pages 221-226 , July 2009

Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes

  • Katerina Papathanassiou

      Affiliations

    • Michaelidion Cardiac Center, University of Ioannina, Ioannina, Greece
    • ,
  • Katerina K. Naka

      Affiliations

    • Michaelidion Cardiac Center, University of Ioannina, Ioannina, Greece
    • Department of Cardiology, University of Ioannina, Ioannina, Greece
    • ,
  • Nikolaos Kazakos

      Affiliations

    • Michaelidion Cardiac Center, University of Ioannina, Ioannina, Greece
    • Intensive Care Unit, Arta General Hospital, Arta, Greece
    • ,
  • Chryssanthi Kanioglou

      Affiliations

    • Department of Endocrinology, University of Ioannina, Ioannina, Greece
    • ,
  • Demetrios Makriyiannis

      Affiliations

    • Department of Endocrinology, Hatzikosta General Hospital, Ioannina, Greece
    • ,
  • Konstantinos Pappas

      Affiliations

    • Department of Cardiology, University of Ioannina, Ioannina, Greece
    • ,
  • Christos S. Katsouras

      Affiliations

    • Michaelidion Cardiac Center, University of Ioannina, Ioannina, Greece
    • Department of Cardiology, University of Ioannina, Ioannina, Greece
    • ,
  • Konstantinos Liveris

      Affiliations

    • Michaelidion Cardiac Center, University of Ioannina, Ioannina, Greece
    • Department of Cardiology, Zakynthos General Hospital, Zakynthos, Greece
    • ,
  • Theofilos Kolettis

      Affiliations

    • Department of Cardiology, University of Ioannina, Ioannina, Greece
    • ,
  • Agathocles Tsatsoulis

      Affiliations

    • Department of Endocrinology, University of Ioannina, Ioannina, Greece
    • ,
  • Lampros K. Michalis

      Affiliations

    • Michaelidion Cardiac Center, University of Ioannina, Ioannina, Greece
    • Department of Cardiology, University of Ioannina, Ioannina, Greece
    • Corresponding Author InformationCorresponding author at: University of Ioannina Medical School, Department of Cardiology, University Campus, Ioannina GR 45 110, Greece. Tel.: +30 26510 97533/97710; fax: +30 26510 97017/97865.

Received 21 July 2008 ,Revised 24 November 2008 ,Accepted 25 November 2008.

References 

  1. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med. 2004;140:945–950
  2. Henderson AH. Endothelial dysfunction: a reversible clinical measure of atherogenic susceptibility and cardiovascular inefficiency. Int J Cardiol. 1997;62:S43–S48
  3. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22:36–52
  4. Fonseca VA. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med. 2007;120:S18–S25
  5. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561–1573
  6. Horio T, Suzuki M, Takamisawa I, et al. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am J Hypertens. 2005;18:1626–1630
  7. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carorid intima-media thickness in type 2 diabetes. JAMA. 2006;296:2572–2581
  8. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2007;298:1180–1188
  9. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO-active Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–1289
  10. UK Prospective Diabetes Study Group. Intensive blood–glucose with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  11. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–2698
  12. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  13. Kravariti M, Naka KK, Kalantaridou SN, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:5088–5095
  14. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–265
  15. Gokce N, Keaney JF, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769–1775
  16. Shimbo D, Grahame-Clarke C, Miyake Y, et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis. 2007;192:197–203
  17. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40:505–510
  18. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol. 2005;46:773–778
  19. Wajcberg E, Sriwijitkamol A, Musi N, DeFronzo RA, Cersosimo E. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone. J Clin Endocrinol Metab. 2007;92:1256–1262
  20. Fernandez M, Triplitt C, Wajcberg E, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care. 2008;31:121–127
  21. Sourij H, Zweiker R, Wascher T. Effects of pioglitazone on endothelial function, insulin sensitivity and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care. 2006;29:1039–1045
  22. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation. 2006;113:867–875
  23. Natali A, Baldeweg S, Taschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27:1349–1357
  24. Mittermayer F, Schaller G, Pleiner J, et al. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab. 2007;92:2574–2580
  25. Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45:1925–1931
  26. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168–1178
  27. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, on behalf of the QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005; 22:399–405.
  28. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. JAMA. 2007;298:1189–1195
  29. Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27:484–490

PII: S0021-9150(08)00841-1

doi: 10.1016/j.atherosclerosis.2008.11.027

Atherosclerosis
Volume 205, Issue 1 , Pages 221-226 , July 2009

Article Tools

* Image Usage & Resolution